BridgeMD
A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY)
EU CTIS ID: 2024-515089-15-00
What this study is testing
To evaluate the efficacy of brepocitinib in participants with non-infectious intermediate uveitis, posterior uveitis, and panuveitis
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult subjects (18-75 years old)
- Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
- Active uveitic disease in at least 1 eye
- Weight > 40 kg with a body mass index ≤ 40 kg/m2
You likely can't join if
- Has confirmed or suspected current diagnosis of infectious uveitis
- History of or have: - Lymphoproliferative disorder; - active malignancy; - cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.); - Thrombosis or cerebrovascular ischemic event within the last 12 months; - a high risk for herpes zoster reactivation; - active or recent infections
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- Taiwan
- United Kingdom
- Australia
- United States
- Argentina
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; Taiwan; United Kingdom; Australia; United States; Argentina. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.